{"product_id":"pypd-ansoff-analysis","title":"(PYPD) PolyPid Ltd. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the Full Ansoff Matrix for Deeper Strategic Insight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis PolyPid Ltd. Ansoff Matrix Analysis maps the company’s growth options across market penetration, market development, product development, and diversification, showing practical strategic moves and risks. The page includes a real preview\/sample of the analysis so you can judge format and substance before buying. Purchase the full version to receive the complete, ready-to-use company-specific Ansoff Matrix report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eD-PLEX100 Phase III in 2 SSI settings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eD-PLEX100 in Phase III for sternal and abdominal SSI prevention is PolyPid Ltd.’s clearest market-share play: same product, same hospital workflows, and a direct path to deeper use in existing surgical care pathways. Surgical site infections affect about 2% to 5% of patients after surgery, so adoption in these two high-volume settings targets a real, recurring need. If Phase III data stay positive, this is the fastest route to penetration without changing the core product or market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and surgeon adoption focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospitals, surgeons, and perioperative teams are the core buyers for D-PLEX100, since adoption happens at the procedure level. Market penetration should stress lower surgical site infection (SSI) risk, smoother OR workflow, and fit with existing perioperative protocols. That keeps PolyPid Ltd. inside the current SSI prevention market, where SSIs still affect about 2% to 5% of surgeries in many settings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePLEX platform differentiation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolyPid’s PLEX platform, a proprietary polymer-lipid encapsulation matrix, is its key edge: it releases antibiotic locally at the wound site, unlike standard systemic prevention. In the Phase 3 SHIELD study, D-PLEX100 cut surgical site infection rates by 59% versus placebo in high-risk colorectal surgery patients. That kind of proof can support share gain in a same-market launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eManufacturing-readiness positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolyPid's manufacturing-readiness position fits market penetration because hospitals buy continuity, not just clinical data. Reliable output, quality control, and supply security help convert D-PLEX100 progress into contracting power and repeat use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuilds hospital trust\u003c\/li\u003e\n\u003cli\u003eSupports supply continuity\u003c\/li\u003e\n\u003cli\u003eTurns trials into share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUnmet medical need in SSI prevention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSSI prevention is still a clear unmet need: SSIs affect about 2% to 5% of surgeries overall, and can reach 20% in high-risk procedures. For PolyPid Ltd, the market-penetration case is simple: cut post-surgical infections where the clinical and economic pain is highest.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2% to 5% SSI rate overall\u003c\/li\u003e\n\u003cli\u003eUp to 20% in high-risk cases\u003c\/li\u003e\n\u003cli\u003eBest fit: infection-prone surgeries\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat makes SSI prevention the core current-market story.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolyPid’s D-PLEX100 Targets a Large, Repetitive SSI Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolyPid Ltd.’s market penetration case centers on D-PLEX100 in the same SSI prevention market, with a Phase III SHIELD result showing a 59% reduction in infections versus placebo in high-risk colorectal surgery. SSIs still affect about 2% to 5% of surgeries overall and up to 20% in high-risk cases, so the current market is large and repetitive. The play is to win more share in existing hospital workflows, not to invent a new use.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSHIELD efficacy\u003c\/td\u003e\n\u003ctd\u003e59%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall SSI rate\u003c\/td\u003e\n\u003ctd\u003e2% to 5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHigh-risk SSI rate\u003c\/td\u003e\n\u003ctd\u003eUp to 20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes PolyPid Ltd.’s growth strategy through market, product, and diversification opportunities\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eHelps clarify PolyPid Ltd.’s growth options with a quick, easy-to-read Ansoff matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, primary-source bibliography that links each Ansoff growth path for PolyPid Ltd. to verifiable references for faster, defensible decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eD-PLEX100 beyond the current clinical footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eD-PLEX100 can move beyond its current Phase III hospital footprint by entering new surgical wards and customer groups after validation. That matters in a market where surgical site infections affect about 2% to 5% of procedures, and global annual surgeries exceed 300 million. For PolyPid Ltd., this is classic market development: the same product, more hospitals, more patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational hospital market entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolyPid, based in Petah Tikva, Israel, can use D-PLEX100 to enter hospitals and surgical centers beyond its home market without changing the product. That is classic market development: the same therapy, new geographies and buyers. For context, the U.S. has over 6,000 hospitals, so each new country can add a large procurement base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader surgical care systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolyPid can expand from trial sites into broader surgical care systems by using the same SSI-prevention platform in larger hospital networks once approvals and evidence are in place. This is a market development move, not a new product move: the product stays the same, but the buyer base widens to integrated health systems that manage many procedures. In 2026, the CDC still estimates about 1 in 31 U.S. hospital patients has at least one HAI, which keeps SSI prevention a real budget issue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProcedure-based expansion within surgery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eD-PLEX100 is being tested in two procedure clusters, sternal and abdominal surgery, which gives PolyPid Ltd. a clear clinical entry point. That is market development: the product stays the same, but the served market broadens into more surgical service lines if the data hold.\u003c\/p\u003e\n\u003cp\u003eIf these studies support infection prevention across more procedure types, PolyPid Ltd. can reuse one platform across hospitals instead of selling a new product each time. That can lift addressable demand without changing the core formulation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame product, wider surgical reach.\u003c\/li\u003e\n\u003cli\u003eSternal and abdominal use cases matter most.\u003c\/li\u003e\n\u003cli\u003eEvidence can open new service lines.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHospital formulary access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFor PolyPid Ltd, hospital formulary access is the fastest market-development lever because a perioperative therapy can win more accounts without changing the product. Surgical site infections still affect about 2% to 5% of surgeries, so hospital buyers have a clear economic reason to add therapies that may cut complications and length of stay.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpand one hospital system at a time.\u003c\/li\u003e\n\u003cli\u003eTarget formulary and procurement teams.\u003c\/li\u003e\n\u003cli\u003eUse the same product, more accounts.\u003c\/li\u003e\n\u003cli\u003eScale across roughly 6,000 U.S. hospitals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolyPid’s Growth Path: More Hospitals, More Countries, More D-PLEX100 Volume\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolyPid Ltd.’s market development case is D-PLEX100’s same product, wider hospital access: expand from trial sites into more surgical wards, health systems, and countries once data and approvals support use. Surgical site infections still affect about 2% to 5% of surgeries, and the U.S. has more than 6,000 hospitals, so each new formulary win can add real volume.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSSI rate\u003c\/td\u003e\n\u003ctd\u003e2% to 5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. hospitals\u003c\/td\u003e\n\u003ctd\u003e6,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal surgeries\u003c\/td\u003e\n\u003ctd\u003e300M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003ePolyPid Ltd. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eD-PLEX100 lifecycle expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eD-PLEX100 lifecycle expansion is product development because PolyPid Ltd. is extending one lead asset into the same surgical market with new labels, use settings, and follow-on data after Phase III. That can lift the value of a single Phase III program without starting a new product. In PolyPid Ltd., one approved label expansion can add revenue per case and widen adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdditional SSI procedure coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolyPid Ltd. can use its 2 late-stage SSI study bases in sternal and abdominal surgery to expand D-PLEX100 into more procedure types. That makes this a product-development move, since it broadens one therapy rather than entering a new market. If new SSI labels lift addressable surgeries by even 1 step at a time, the product’s surgical utility deepens fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePLEX-based next-generation assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePLEX is PolyPid Ltd.'s product engine, not a one-drug asset, because the same encapsulation matrix can be adapted for new therapies. That makes each new PLEX-based program a pipeline builder, not a one-off bet. In Ansoff terms, this is product development: reuse the platform, add new indications, and expand value without rebuilding the core delivery system.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFormulation and delivery refinement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolyPid Ltd. is still refining formulation, release profile, and delivery performance inside its PLEX-based family, which keeps the work squarely in existing product development rather than a new market bet. In advanced-stage development, those tweaks matter because a cleaner local release can lift efficacy and reduce repeat procedures, which helps later commercialization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStay inside the PLEX platform\u003c\/li\u003e\n\u003cli\u003eImprove release control\u003c\/li\u003e\n\u003cli\u003eSupport later market launch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat matters because PolyPid’s lead asset, D-PLEX100, is still in late-stage development, so small gains in delivery consistency can translate into better clinical and regulatory positioning before scale-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCombination-use perioperative products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolyPid Ltd. can extend D-PLEX100 by adding combination-use perioperative variants that fit standard surgical steps, so the product stays in the same market while improving fit and use. Surgical site infections still affect about 2%–5% of clean procedures, and higher-risk cases can run much higher, so even small workflow gains can matter.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame market, better fit\u003c\/li\u003e\n\u003cli\u003eAligns with perioperative protocols\u003c\/li\u003e\n\u003cli\u003eTargets infection risk at surgery\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolyPid’s D-PLEX100 Expands SSI Control in Surgery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolyPid Ltd.’s product development is D-PLEX100 line extension inside the same surgical market: new labels, use settings, and follow-on data for SSI control. SSI rates are still about 2%–5% in clean surgery, so even small fit gains can matter. The PLEX platform can also support new perioperative variants without changing the core delivery system.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSSI risk\u003c\/td\u003e\n\u003ctd\u003e2%–5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore asset\u003c\/td\u003e\n\u003ctd\u003eD-PLEX100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMode\u003c\/td\u003e\n\u003ctd\u003eSame market, new use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePLEX platform beyond SSI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePLEX is PolyPid Ltd.’s drug-delivery matrix, so it can support more than one product family and move beyond surgical site infection prevention into new therapeutic areas. That makes diversification the cleanest Ansoff move: one platform, new products, new markets. In 2025, PolyPid still centered value on D-PLEX100 and Phase 3 SSI work, so platform expansion is the main path to widen its commercial base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew hospital therapeutics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolyPid’s diversification into new hospital therapeutics fits its position near the inpatient care setting and can extend the platform beyond surgical site infections (SSI). With healthcare-associated infections affecting about 1 in 31 hospitalized patients on any given day, new high-unmet-need uses could open a fresh product-market mix. For a platform company, this is a natural diversification move, not a stretch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlatform licensing opportunities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolyPid Ltd.’s proprietary PLEX encapsulation matrix can be licensed or partnered into new third-party uses, so the business can enter wider markets without funding every program itself. That matters because it shifts value from one lead asset to a platform model, with upside from milestone fees, royalties, and co-development. In 2025, this kind of deal flow is often more capital-light than building each indication alone.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBroader biopharmaceutical pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFounded in 2008, PolyPid can use its advanced-stage drug-delivery know-how to add new molecules and delivery-enabled programs. That would cut dependence on D-PLEX100, which is still the company’s main value driver, and lower single-asset risk. In Ansoff terms, this is classic diversification: same science base, new product bets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses existing delivery platform\u003c\/li\u003e\n\u003cli\u003eReduces D-PLEX100 concentration risk\u003c\/li\u003e\n\u003cli\u003eFits a 2008-founded biotech\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommercialization outside SSI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolyPid Ltd.’s strategy goes beyond development and targets commercialization, so expansion outside surgical site infection would open new demand pools and sales channels. Adding more therapeutic categories would lower dependence on one product and one infection segment, which reduces both product risk and market exposure. In Ansoff terms, that is a clear move from single-market focus toward broader market development.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuilds new commercial channels.\u003c\/li\u003e\n\u003cli\u003eSpreads risk across categories.\u003c\/li\u003e\n\u003cli\u003eReduces SSI concentration.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolyPid’s PLEX Platform Cuts Single-Asset Risk in Hospital Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolyPid’s diversification case is platform-led: PLEX can support new products beyond D-PLEX100, so one chemistry base can reach new hospital uses. That matters in a market where healthcare-associated infections hit about 1 in 31 hospitalized patients daily, and it cuts single-asset risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform\u003c\/td\u003e\n\u003ctd\u003ePLEX\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMain asset\u003c\/td\u003e\n\u003ctd\u003eD-PLEX100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeed\u003c\/td\u003e\n\u003ctd\u003e1 in 31\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234834424073,"sku":"pypd-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/pypd-ansoff-matrix.webp?v=1785729441","url":"https:\/\/dcfanalyst.com\/products\/pypd-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}